Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4170U | ISIN: US89357L5012 | Ticker-Symbol:
NASDAQ
26.06.25 | 21:23
8,450 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRANSCODE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TRANSCODE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TRANSCODE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Transcode Therapeutics, Inc. - 8-K, Current Report2
28.05.TransCode Therapeutics appoints RNA expert to advisory board9
28.05.TransCode Therapeutics beruft RNA-Experten in den Beirat6
08.05.TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported14015 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with...
► Artikel lesen
05.05.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split247BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively...
► Artikel lesen
02.05.TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall2
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln
02.05.TransCode Therapeutics approves reverse stock split to meet Nasdaq rules2
02.05.TransCode Therapeutics genehmigt Aktienzusammenlegung zur Einhaltung der NASDAQ-Regeln3
02.05.Transcode Therapeutics, Inc. - 8-K, Current Report4
02.05.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split124Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)...
► Artikel lesen
01.05.TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer100A total of 13 patients treated with four escalating doses of TTX-MC138 No significant safety or dose limiting toxicities reported Two patients have so far maintained...
► Artikel lesen
01.05.EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug3
30.04.Transcode Therapeutics, Inc. - 10-K/A, Annual Report4
21.04.Transcode Therapeutics, Inc. - 8-K, Current Report13
15.04.Transcode Therapeutics, Inc. - 10-K, Annual Report6
31.03.Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4055
27.03.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138177First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being...
► Artikel lesen
25.03.Transcode Therapeutics, Inc. - 8-K, Current Report1
25.03.TransCode Therapeutics Announces $10M Stock And Warrant Offering1
24.03.TransCode Therapeutics stock slides after announces to raise $10M securities offering5
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1